Author

W. A. Wegener

Institution: Immunomedics (United States)

Observed institutions: Mayo Clinic, Children's Hospital of Philadelphia, Baylor College of Medicine, Cornell University, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nantes, Hôpital Lyon Sud, Immunomedics (United States), Weill Cornell Medicine, New York University, Columbia University

OpenAlex ID: A5113715779

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography

2008 · C. Bodet-Milin, F. Kraeber-Bodere, et al. · Haematologica · 40

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

2014 · T. E. Witzig, M. B. Tomblyn, et al. · Haematologica · 31

Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL

2006 · F. Morshhauser, J. P. Leonard, et al. · Journal of Clinical Oncology · 15

Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results

2007 · F. Morschhauser, J. P. Leonard, et al. · Journal of Clinical Oncology · 9

Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab

2008 · D. M. Goldenberg, C. Chang, et al. · Journal of Clinical Oncology · 2

Chemoimmunotherapy reinduction with epratuzumab in children with ALL with marrow relapse: A Children's Oncology Group (COG) pilot study (ADVL04P2)

2007 · E. A. Raetz, M. S. Cairo, et al. · Journal of Clinical Oncology · 2

Works count: 6

Citation count: 101

H-index: 4

I10-index: 3